Liaoning Chengda Biotechnology Co.,Ltd. (SHA:688739)
China · Delayed Price · Currency is CNY 24.38
-0.41 (-1.65%)
Apr 17, 2026, 4:00 PM EDT
SHA:688739 Revenue
In the year 2025, Liaoning Chengda Biotechnology had annual revenue of 1.39B CNY, down -17.06%. Liaoning Chengda Biotechnology had revenue of 294.40M in the quarter ending December 31, 2025, a decrease of -21.19%.
Revenue
1.39B
Revenue Growth
-17.06%
P/S Ratio
7.21
Revenue / Employee
769.39K
Employees
1,788
Market Cap
10.02B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.39B | -285.95M | -17.06% |
| Dec 31, 2024 | 1.68B | -73.86M | -4.22% |
| Dec 31, 2023 | 1.75B | -64.90M | -3.58% |
| Dec 31, 2022 | 1.81B | -273.04M | -13.08% |
| Dec 31, 2021 | 2.09B | 92.47M | 4.63% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Youcare Pharmaceutical Group | 2.45B |
| China Resources Boya Bio-pharmaceutical Group Co.,Ltd | 2.06B |
| Jiangsu Sinopep-Allsino Biopharmaceutical | 1.94B |
| Aurisco Pharmaceutical | 1.70B |
| Jiangxi Fushine Pharmaceutical | 1.18B |
| Shanghai Medicilon | 1.08B |
| Bio-Thera Solutions | 933.69M |
| Sino Biological,Inc. | 699.56M |